Roth Capital Issues Pessimistic Outlook for CELZ Earnings

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) – Analysts at Roth Capital reduced their FY2027 earnings estimates for shares of Creative Medical Technology in a research note issued to investors on Friday, March 21st. Roth Capital analyst J. Aschoff now forecasts that the company will earn $3.00 per share for the year, down from their prior estimate of $3.26. The consensus estimate for Creative Medical Technology’s current full-year earnings is ($3.19) per share.

Creative Medical Technology Price Performance

CELZ stock opened at $2.64 on Monday. The stock has a market capitalization of $4.61 million, a P/E ratio of -0.69 and a beta of 1.70. Creative Medical Technology has a fifty-two week low of $1.96 and a fifty-two week high of $6.90. The business has a 50-day moving average of $3.77 and a 200-day moving average of $3.26.

Institutional Trading of Creative Medical Technology

A hedge fund recently bought a new stake in Creative Medical Technology stock. Geode Capital Management LLC acquired a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned approximately 0.59% of Creative Medical Technology at the end of the most recent reporting period. 1.42% of the stock is currently owned by institutional investors and hedge funds.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.